Pharma giant Bayer is focused on executing smaller licensing deals and acquisitions as it bulks up its portfolio, says Juergen Eckhardt, its global head of business development and licensing.
The big picture: Licensing deals dominated biopharma dealmaking last year and have already driven several major transactions in the first weeks of 2026.
